Jose F. Falantes
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Journal: Cancer
Published: August 02, 2024
Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.
Journal: British journal of haematology
Published: April 23, 2024
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Journal: Leukemia research
Published: July 06, 2023
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 26, 2022
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
Journal: Cancers
Published: April 14, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 25, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Journal: Cancer
Published: August 09, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Journal: The New England journal of medicine
Published: January 09, 2020
Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 18, 2018
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
Journal: Annals of hematology
Published: September 19, 2017
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Journal: The Lancet. Haematology
Published: September 13, 2017
Last Updated: 09/26/2026